CClinicalTrials.gg
CompletedNCT06548022Group PM+Updated Mar 30, 2026

Rare Group Problem Management Plus

An interventional study of Rare Group Problem Management Plus in Anxiety, Depressive Symptoms and Post-traumatic Stress Disorder, sponsored by Children's National Research Institute. Completed at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Children's National Research Institute · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Feb 2024, registered Jul 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Study summary

Participants are being asked to be in the study if they are the parent or legal guardian of a child (>1 year or \<18 years old) with a rare condition.

The group based psychoeducational intervention is called Rare Group Problem Management Plus.

Rare Group PM Plus may help adults with practical and emotional problems. It is a group program (there will be other men or women with similar problems) It happens once a week for 5 weeks (each session lasts 90 minutes)

Participants will complete assessments before they start Rare Group PM+. Participants will also complete the same assessments within a few weeks of completing Rare Group PM+. Assessments should only take one hour.

Study visits are by Telemedicine. Participants will need a smart phone or tablet. If they do not have a smart phone or tablet, the study team will help with this.

Participants will not receive any materials or money or medication.

Read the detailed description

Participants are being asked to be in the study because they are the parent or legal guardian of a child (infancy up to 21 years old) with a rare condition.

The group based psychoeducational intervention is called Rare Group Problem Management (PM) Plus intervention.

Rare Group PM Plus may help adults with practical and emotional problems It is a group program (there will be other men or women with similar problems) It happens once a week for 5 weeks (each session lasts 90 minutes)

Investigators will be recruiting for 3 groups of 10 families each, for a total of 30 families who will participate in this study from Children's National Hospital.

There are 7 study visits.

Study Timeline:

Study visit 1: Assessment-Before Group PM+ Study visit 2: Session 1-Managing Stress Study visit 3: Session 2-Managing Problems Study visit 4: Session 3-Get Going, Keep Doing Study visit 5: Session 4-Strengthening Social Support Study Visit 6: Session 5-Staying Well and Looking Forward Study Visit 7: Assessment within 2 weeks after complete Group PM+

Sessions will occur over Zoom Telehealth and facilitated by a licensed clinical psychologist and a genetic counselor trainee.

Investigators will use chi-square tests and Fisher's exact test to measure changes from baseline to 2 weeks post-intervention. Investigators will also collect qualitative data on what participants liked about the intervention, what they did not like, and what they think will improve the intervention.

02

Conditions studied

  • Anxiety
  • Depressive Symptoms
  • Post-traumatic Stress Disorder
  • Problems Psychosocial

Keywords

  • rare disease
  • pediatric
  • family caregiver
  • psychoeducation
  • group intervention
03

In context

Anxiety Disorders

4,868 studies on the registry are indexed under Anxiety Disorders; 1,390 are open to participants now.

This study's enrollment of 8 is below the median of 80 across 4,174 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Children's National Research Institute is the lead sponsor of 124 studies on the registry; 45 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

    • Family caregiver aged 18 years or older of a child with a rare disease from infancy to age 21 years.

      • Understands and speaks English or Spanish. Reading or health literacy is not required.
      • Signed consent.
      • Signed waiver of assent for child.

Exclusion criteria

Exclusion Criteria:

  • Family caregiver is under the age of 18 years.
  • Child with the rare disease is over the age of 21 years.
  • Family caregiver is actively suicidal, homicidal, or psychotic.
  • Family caregiver is impaired (cognitively or by drugs or alcohol).
  • Family caregiver has a low level of distress.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Rare Group PM Plus

    Rare Group PM Plus consists of 5 weekly sessions. Each session lasts 90 minutes. Session 1: Managing Stress Session 2: Managing Problems Session 3: Get Going, Keep Doing Session 4: Strengthening Social Support Session 5: Staying Well and Looking Forward

    Behavioral: Rare Group Problem Management Plus

Interventions

  • BehavioralRare Group Problem Management Plus

    The World Health Organization's Group Problem Management Plus (Group PM+) intervention has been demonstrated to effectively provide psychological help for adults impaired by distress in communities exposed to adversity. Investigators will test an adapted model for use on-line and with family caregivers of children with rare diseases. Managing Stress. Teaching participants a brief stress management strategy will help them better manage problems related to anxiety and stress. Managing Problems. This is a strategy to apply in situations where a participant is experiencing practical problems (e.g. conflict in the family). Get Going, Keep Doing. This strategy targets depression and inactivity. Strengthening Social Support. Individuals with emotional problems can be isolated from supportive people and organizations. Strengthening social support promotes well-being. Staying Well and Looking Forward. This is a review, ends with a closing ceremony.

06

What researchers measure

Primary outcomes

  1. Acceptability

    As measured by retention at 2 weeks post-intervention assessment

    Time frame: 2 weeks post-intervention (Session 5)

07

Study locations

1 site
  • Children's National Hospital
    Washington D.C., District of Columbia 20010, United States
08

References and documents

Publications

  • Bogart KR, Irvin VL. Health-related quality of life among adults with diverse rare disorders. Orphanet J Rare Dis. 2017 Dec 7;12(1):177. doi: 10.1186/s13023-017-0730-1. PubMed 29212508 ↗
  • Bogart KR, Dermody SS. Relationship of rare disorder latent clusters to anxiety and depression symptoms. Health Psychol. 2020 Apr;39(4):307-315. doi: 10.1037/hea0000840. Epub 2019 Dec 19. PubMed 31855040 ↗
  • Rothrock NE, Amtmann D, Cook KF. Development and validation of an interpretive guide for PROMIS scores. J Patient Rep Outcomes. 2020 Feb 28;4(1):16. doi: 10.1186/s41687-020-0181-7. PubMed 32112189 ↗
  • Uhlenbusch N, Lowe B, Harter M, Schramm C, Weiler-Normann C, Depping MK. Depression and anxiety in patients with different rare chronic diseases: A cross-sectional study. PLoS One. 2019 Feb 20;14(2):e0211343. doi: 10.1371/journal.pone.0211343. eCollection 2019. PubMed 30785907 ↗
  • Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x. PubMed 11556941 ↗
  • Saunders R, Moinian D, Stott J, Delamain H, Naqvi SA, Singh S, Wheatley J, Pilling S, Buckman JEJ. Measurement invariance of the PHQ-9 and GAD-7 across males and females seeking treatment for common mental health disorders. BMC Psychiatry. 2023 Apr 28;23(1):298. doi: 10.1186/s12888-023-04804-x. PubMed 37118684 ↗
  • Lai X, Jiang Y, Sun Y, Zhang Z, Wang S. Prevalence of depression and anxiety, and their relationship to social support among patients and family caregivers of rare bone diseases. Orphanet J Rare Dis. 2023 Jan 26;18(1):18. doi: 10.1186/s13023-022-02611-3. PubMed 36703212 ↗
  • Xiao SY. et al. The theoretical basis and applications of Social Support Rating Scale (SSRS). Journal of Clinical Psychiatry. 1994;4:98-100.
  • Kenny T, et al. The importance of psychological support for parents and caregivers of children with a rare disease diagnosis. Rare Disease and Orphan Drugs Journal. 2022;1(2):7.
  • Anderson M, Elliott EJ, Zurynski YA. Australian families living with rare disease: experiences of diagnosis, health services use and needs for psychosocial support. Orphanet J Rare Dis. 2013 Feb 11;8:22. doi: 10.1186/1750-1172-8-22. PubMed 23398775 ↗
  • Scharping M, Brennenstuhl H, Garbade SF, Wild B, Posset R, Zielonka M, Kolker S, Haun MW, Opladen T. Unmet Needs of Parents of Children with Urea Cycle Disorders. Children (Basel). 2022 May 12;9(5):712. doi: 10.3390/children9050712. PubMed 35626889 ↗
  • Lyon ME, Fraser JL, Thompkins JD, Clark H, Brodie N, Detwiler K, Torres C, Guerrera MF, Younge T, Aoun S, Trujillo Rivera EA. Advance Care Planning for Children With Rare Diseases: A Pilot RCT. Pediatrics. 2024 Jun 1;153(6):e2023064557. doi: 10.1542/peds.2023-064557. PubMed 38699801 ↗
  • Peterman AH, Fitchett G, Brady MJ, Hernandez L, Cella D. Measuring spiritual well-being in people with cancer: the functional assessment of chronic illness therapy--Spiritual Well-being Scale (FACIT-Sp). Ann Behav Med. 2002 Winter;24(1):49-58. doi: 10.1207/S15324796ABM2401_06. PubMed 12008794 ↗
  • Cooper B, Kinsella GJ, Picton C. Development and initial validation of a family appraisal of caregiving questionnaire for palliative care. Psychooncology. 2006 Jul;15(7):613-22. doi: 10.1002/pon.1001. PubMed 16287207 ↗
  • Toledano-Toledano F, Moral de la Rubia J, Dominguez-Guedea MT, Nabors LA, Barcelata-Eguiarte BE, Rocha-Perez E, Luna D, Leyva-Lopez A, Rivera-Rivera L. Validity and Reliability of the Beck Anxiety Inventory (BAI) for Family Caregivers of Children with Cancer. Int J Environ Res Public Health. 2020 Oct 23;17(21):7765. doi: 10.3390/ijerph17217765. PubMed 33114144 ↗
  • Alimujiang A, Wiensch A, Boss J, Fleischer NL, Mondul AM, McLean K, Mukherjee B, Pearce CL. Association Between Life Purpose and Mortality Among US Adults Older Than 50 Years. JAMA Netw Open. 2019 May 3;2(5):e194270. doi: 10.1001/jamanetworkopen.2019.4270. PubMed 31125099 ↗
  • Hill PL, Turiano NA. Purpose in life as a predictor of mortality across adulthood. Psychol Sci. 2014 Jul;25(7):1482-6. doi: 10.1177/0956797614531799. Epub 2014 May 8. PubMed 24815612 ↗
  • Boettcher J, Filter B, Denecke J, Hot A, Daubmann A, Zapf A, Wegscheider K, Zeidler J, von der Schulenburg JG, Bullinger M, Rassenhofer M, Schulte-Markwort M, Wiegand-Grefe S. Evaluation of two family-based intervention programs for children affected by rare disease and their families - research network (CARE-FAM-NET): study protocol for a rater-blinded, randomized, controlled, multicenter trial in a 2x2 factorial design. BMC Fam Pract. 2020 Nov 20;21(1):239. doi: 10.1186/s12875-020-01312-9. PubMed 33218310 ↗
  • First Michael B, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Clinical Trials Version (SCID-CT). New York: Biometrics Research, New York State Psychiatric institute, 2007.
  • Witt S, Schuett K, Wiegand-Grefe S, Boettcher J, Quitmann J. Living with a rare disease - experiences and needs in pediatric patients and their parents. Orphanet J Rare Dis. 2023 Aug 11;18(1):242. doi: 10.1186/s13023-023-02837-9. PubMed 37568186 ↗
  • Delisle VC, Gumuchian ST, Rice DB, Levis AW, Kloda LA, Korner A, Thombs BD. Perceived Benefits and Factors that Influence the Ability to Establish and Maintain Patient Support Groups in Rare Diseases: A Scoping Review. Patient. 2017 Jun;10(3):283-293. doi: 10.1007/s40271-016-0213-9. PubMed 28004275 ↗
  • Ashtari S, Taylor A. Patients With Rare Diseases and the Power of Online Support Groups: Implications for the Medical Community. JMIR Form Res. 2023 Sep 14;7:e41610. doi: 10.2196/41610. PubMed 37707878 ↗
  • Titgemeyer SC, Schaaf CP. Facebook Support Groups for Rare Pediatric Diseases: Quantitative Analysis. JMIR Pediatr Parent. 2020 Nov 19;3(2):e21694. doi: 10.2196/21694. PubMed 33211019 ↗
  • McCarthy SR, Golembiewski EH, Gravholt DL, Clark JE, Clark J, Fischer C, Mulholland H, Babcock K, Montori VM, Jones A. Documentation of Psychosocial Distress and Its Antecedents in Children with Rare or Life-Limiting Chronic Conditions. Children (Basel). 2022 May 5;9(5):664. doi: 10.3390/children9050664. PubMed 35626841 ↗
  • World Health Organization Group Problem Management Plus (Group PM+): group psychological help for adults impaired by distress in communities exposed to adversity. Generic field-trial version 1.0. 30 August 2020. https://www.who.int/publications/i/item/9789240008106
  • Jordans MJD, Kohrt BA, Sangraula M, Turner EL, Wang X, Shrestha P, Ghimire R, Van't Hof E, Bryant RA, Dawson KS, Marahatta K, Luitel NP, van Ommeren M. Effectiveness of Group Problem Management Plus, a brief psychological intervention for adults affected by humanitarian disasters in Nepal: A cluster randomized controlled trial. PLoS Med. 2021 Jun 17;18(6):e1003621. doi: 10.1371/journal.pmed.1003621. eCollection 2021 Jun. PubMed 34138875 ↗
  • de Graaff AM, Cuijpers P, Twisk JWR, Kieft B, Hunaidy S, Elsawy M, Gorgis N, Bouman TK, Lommen MJJ, Acarturk C, Bryant R, Burchert S, Dawson KS, Fuhr DC, Hansen P, Jordans M, Knaevelsrud C, McDaid D, Morina N, Moergeli H, Park AL, Roberts B, Ventevogel P, Wiedemann N, Woodward A, Sijbrandij M; STRENGTHS Consortium; STRENGTHS consortium. Peer-provided psychological intervention for Syrian refugees: results of a randomised controlled trial on the effectiveness of Problem Management Plus. BMJ Ment Health. 2023 Feb;26(1):e300637. doi: 10.1136/bmjment-2022-300637. Epub 2023 Feb 8. PubMed 36789918 ↗
  • Weathers et al., The PTSD Checklist for DSM-5 (PCL-5) - Standard [Measurement instrument]. https://www.ptsd.va.gov
  • Czachowski S, Seed P, Schofield P, Ashworth M. Measuring psychological change during cognitive behaviour therapy in primary care: a Polish study using 'PSYCHLOPS' (Psychological Outcome Profiles). PLoS One. 2011;6(12):e27378. doi: 10.1371/journal.pone.0027378. Epub 2011 Dec 15. PubMed 22194783 ↗
  • Ustun, et al. and World Health Organization. Measuring health and disability: manual for WHO Disability Assessment Schedule (WHODAS 2.0). World Health Organization 2010. Manual 16, June 2016.
  • Ali AM, Schwalk DE, Lyon ME. Adapting and Beta Testing Rare Group Problem Management Plus for Family Caregivers of Children with Rare Diseases. (April 30, 2025). Poster. 2025 Awardee Medical Student Research Day, Abdulla Ali, in the category of Clinical and Translational Research. George Washington University School of Medicine and Health Sciences, Washington DC.

Individual participant data

Plan to share: No — No individual participant data will be available to other researchers for this development and adaptation study.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06548022
Lead sponsor
Children's National Research Institute
Collaborators
Travere Therapeutics, Inc.
Responsible party
Maureen Lyon (Clinical Health Psychologist, Children's National Research Institute) — Principal investigator
First posted
Aug 12, 2024
Start date
Feb 5, 2024
Primary completion
Jun 25, 2025
Completion
Nov 30, 2025
Last update
Mar 30, 2026

Study contacts

Maureen Lyon, PhD
principal investigator · Children's National Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion